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Abstract
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disease, characterised by the formation
of insoluble amyloidogenic plaques and neurofibrillary tangles. Beta amyloid (Ab) peptide is one of the main
constituents in Ab plaques, and is thought to be a primary causative agent in AD. Neurons are likely to be
exposed to chronic, sublethal doses of Ab over an extended time during the pathogenesis of AD, however most
studies published to date using in vitro models have focussed on acute studies. To experimentally model the
progressive pathogenesis of AD, we exposed primary cortical neurons daily to 1 μMo fA b1-40 over 7 days and
compared their survival with age-similar untreated cells. We also investigated whether chronic Ab exposure affects
neuronal susceptibility to the subsequent acute excitotoxicity induced by 10 μM glutamate and assessed how Ca
2+
and K
+ homeostasis were affected by either treatment.
Results: We show that continuous exposure to 1 μMA b1-40 for seven days decreased survival of cultured cortical
neurons by 20%. This decrease in survival correlated with increased K
+ efflux from the cells. One day treatment with 1
μMA b followed by glutamate led to a substantially higher K
+ efflux than in the age-similar untreated control. This
difference further increased with the duration of the treatment. K
+ efflux also remained higher in Ab treated cells 20
min after glutamate application leading to 2.8-fold higher total K
+ effluxed from the cells compared to controls. Ca
2+
uptake was significantly higher only after prolonged Ab treatment with 2.5-fold increase in total Ca
2+ uptake over 20
min post glutamate application after six days of Ab treatment or longer (P < 0.05).
Conclusions: Our data suggest that long term exposure to Ab is detrimental because it reduces the ability of
cortical neurons to maintain K
+ and Ca
2+ homeostasis in response to glutamate challenge, a response that might
underlie the early symptoms of AD. The observed inability to maintain K
+ homeostasis might furthermore be useful
in future studies as an early indicator of pathological changes in response to Ab.
Background
Alzheimer’s disease (AD) is the most common form of
dementia within the ageing population and accounts
for between 50% and 60% of dementia cases [1]. Suf-
ferers of AD experience progressive loss of memory
and cognitive abilities that eventually lead to dementia
and death. The pathological hallmarks of the disease
include extracellular b-amyloid (Ab) plaques, intracel-
lular neurofibrillary tangles (NFTs) and dystrophic
neurites (DNs) [2]. The Ab peptide is one of the main
constituents in Ab plaques, and is thought to be a
primary causative agent in AD, significantly contribut-
ing towards AD pathogenesis.
AD is a progressive disease which develops over many
years, even decades. Therefore the pathogenesis of AD
does not entail a sudden insult of Ab which causes wide-
spread neuronal death within the brain. Instead, there
appears to be a gradual progression of the disease which
involves the accumulation of soluble Ab within the brain
due to the chronic imbalance between production and
clearance of Ab. This gradual accumulation of Ab over
extended periods of time leads to the formation of the
insoluble Ab aggregates which form the characteristic
plaques, but it also modifies neuronal function. It is diffi-
cult to correlate early stages of AD pathogenesis with the
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Studies using transgenic mice which express human
mutant Ab precursor peptide (APP, Tg2576 mice)
demonstrated that the increase of Ab1-40 and Ab1-42 over
several months was accompanied by deficits in normal
learning and memory [3,4]. When the Ab load was mini-
mal, mice demonstrated normal spatial learning and
memory, indicating that the gradual build up of Ab cor-
related with the physiological changes associated with
AD. Studies have demonstrated that many molecular
forms of Ab are neurotoxic causing neuronal cell death
in vitro and neuronal loss in vivo. For example, synthetic
Ab peptides were toxic to hippocampal and cortical neu-
rons in culture [5,6].
Neurons are likely to be exposed to sublethal doses of
Ab over an extended time during the pathogenesis of
AD. However studies to date have not developed an
experimental model of this chronic exposure. There
have been numerous in vitro models used to examine
Ab neurotoxicity using various forms and concentration
of the peptide, over the short term. For instance Desh-
pande and colleagues examined the toxicity of a single
dose of 5 μM fibrillar Ab1-42 and Ab-derived diffusible
ligands on human cortical neuron cultures for up to
24 hours [6]. At the same time studies examining the
c h r o n i ce x p o s u r eo fn e u r o n st oA b at sublethal doses
would provide valuable information relative to the
physiological processes which occur in the AD brain.
The accumulation of toxic Ab peptide aggregates in
AD brain is thought to trigger the extensive synaptic
loss and neurodegeneration linked to cognitive decline,
an idea that underlies the ‘amyloid hypothesis’ of AD
etiology in both the familial and sporadic forms of the
disease [7]. Recent reports strongly suggest that in the
initial stages of AD, glutamate receptors are dysregu-
lated by Ab accumulation resulting in disruption of glu-
tamatergic synaptic transmission which parallels early
cognitive deficits [8]. High concentrations of glutamate
have been documented to cause neuronal degeneration
in various in vivo and in vitro models [9,10]. Therefore,
it would be of interest whether chronic neuron exposure
to Ab would sensitise them to excitotoxicity caused by
increased glutamate concentration.
Excessive glutamatergic stimulation is associated with
an increase in intracellular calcium ([Ca
2+]i). Although
Ca
2+ is necessary for a number of physiological pro-
cesses, excessive amounts may lead to neuronal dysfunc-
tion and cell death. Neuronal increases in [Ca
2+]i can
activate a number of enzymes, such as phospholipases,
proteases, endonucleases and nitric oxide synthase
(NOS) that are associated with neuronal cell death [11].
Increases in cytosolic Ca
2+ levels were observed in AD
mouse models strongly supporting the theory that Ca
2+
dysregulation is involved in AD [12-14]. Recent data
also indicate that rodent and human Ab modulate K
+
currents [15]. Voltage-dependent K
+ (Kv) channels act
as potent modulators of diverse excitatory events that
are linked to glutamatergic neurotransmission [16]
including modulation of Ca
2+ uptake. Changes in ion
fluxes are one of the earliest events in neural responses
to Ab treatment that precede neuron survival. There-
fore, delineation between neuronal ability to maintain
Ca
2+ and K
+ homeostasis during prolonged Ab treat-
ment and their viability might provide inside into
mechanisms underlying processes of neurodegeneration.
To experimentally model the progressive pathogenesis
of AD, primary cortical neurons were exposed to sub-
lethal doses of Ab1-40 over an extended period of time
of 7 days. In this study we compared survival of cortical
neurons treated for different periods of time with Ab1-40
and correlated them to the neuron’s ability to maintain
homeostasis of Ca
2+ and K
+ ions under the same condi-
tions. Finally, we investigated whether prolonged expo-
sure to relatively low Ab1-40 (1 μM) increased neuronal
susceptibility to subsequent acute excitotoxicity induced
by the neurotransmitter glutamate.
Results
Continuous exposure to Ab1-40 is mildly neurotoxic to
cultured cortical neurons
We first examined whether chronic exposure of mature
neurons to low levels of Ab caused cell death. Cortical
neurons were maintained for 6 DIV, by which time they
had formed a dense meshwork of neuritic processes.
They were then treated with soluble monomeric Ab1-40
(1 μM) daily for up to a further seven days. Daily deter-
mination of neuronal viability by an Alamar Blue assay
revealed that Ab1-40 treatment did not reduce cell viabi-
lity for cells treated for up to six days (Figure 1). How-
ever, by seventh day of the treatment neuronal viability
decreased by 20% (P < 0.05).
Acute exposure to low doses of Ab1-40 does not change K
+ and Ca
2+ fluxes from neurons
Inability to maintain Ca
2+ homeostasis has been strongly
implicated in AD [12-14]. Therefore, we investigated
whether ion homeostasis would be affected by Ab.W e
first examined whether acute exposure of mature neu-
rons to low levels of a soluble Ab1-40 affect changes in
K
+ and Ca
2+ fluxes. We therefore performed simulta-
neous recordings of K
+ and Ca
2+ fluxes from cortical
neurons using Microelectrode Ion Flux Estimation
(MIFE) after an acute application of 1 μMAb1-40 to pri-
mary 14 DIV neurons (Additional file 1, Figure S1).
MIFE enables sensitive, real time measurement of ion
fluxes across cell membranes in a variety of cell models
and is non-invasive [17,18]. No changes in net K
+ and
Ca
2+ fluxes were observed within 15 min post treatment
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further experiments. We also found no changes in net K
+ and Ca
2+ fluxes in response to vehicle (Additional file
2, Figure S2) further confirming our findings.
Continuous exposure to Ab1-40 increases K
+ efflux from
neurons
Under physiological conditions neurons are continu-
ously exposed to low doses of Ab.T os i m u l a t et h o s e
conditions we treated neurons with 1 μMA b over a
prolonged period of time measuring ion fluxes of inter-
est. Therefore, we investigated whether chronic treat-
ment with soluble Ab1-40 can affect the ability of
cortical neurons to maintain Ca
2+ homeostasis (Figure
2 ) .W ea l s ot e s t e dw h e t h e rK
+ homeostasis would be
affected by Ab treatments since fluxes of this ion are
pivotal to neuronal activity. No difference was observed
in the level of Ca
2+ fluxes between untreated cells, and
cells treated with Ab1-40 for up to eight days (Figure
2 A ) .A tt h es a m et i m es i g n i ficant differences were
observed in K
+ fluxes (Figure 2B). While the K
+ flux
was similar in control cultures and those treated with
Ab1-40 for one and three days, treatment with a soluble
monomeric Ab1-40 (1 μM) daily for a period of six days
or longer led to a significantly higher K
+ efflux from the
neural cells. Specifically, six and eight day Ab treatment
resulted in four- and three-fold increase in K
+ efflux
from the cells, respectively (P < 0.02)suggesting that
chronic treatment with Ab1-40 leads to a reduced capa-
city of neurons to maintain K
+ homeostasis.
Chronic exposure to Ab1-40 does not decrease neuronal
viability following excitotoxic stress but does affect
subsequent K
+ homeostasis
We next investigated whether neurons exposed to pro-
longed Ab1-40 treatment had increased susceptibility to
subsequent excitotoxicity induced by 200 μM glutamate.
While glutamate treatment for 24 hours killed approxi-
mately 20% of neurons in the absence of any Ab1-40
treatment (Figure 3A), we found that seven days of pre-
treatment with Ab1-40 did not further elevate neuronal
susceptibility to glutamate-induced neurotoxicity (Figure
3B). We then examined K
+ and Ca
2+ fluxes in neurons
which were treated with 1 μMA b1-40 d a i l yf o rap e r i o d
from one to eight days and then challenged with 10 μM
Figure 1 Viability of cortical neurons in response to daily
treatments of Ab1-40. 6DIV cortical neurons were treated daily with
1 μMA b1-40 for seven days. Neuronal viability was recorded at Day
2, 3, 4, 6 and 7 of treatment and expressed as the percentage of
surviving Ab-treated neurons compared to age-matched, untreated
controls. At Day 7, neuronal viability was significantly lower than the
vehicle-treated controls. *P < 0.05 between Ab1-40 treated and age-
similar control on the same day of measurement. All data are
means ± standard error of the mean (SEM), n = 4.
Figure 2 Effect of daily treatment with Ab1-40 on K
+ and Ca
2+
fluxes. After 6DIV, cortical neurons were treated daily with 1 μM
Ab1-40 for up to eight days. Net ion fluxes were recorded daily from
monolayers of cells grown on glass cover slips treated with poly-L-
lysine for cell adherence. Data was acquired non-invasively using
the microelectrode MIFE technique. Steady-state fluxes of K
+ (A)
and Ca
2+ (B) are shown for one, three, six, and eight day treatment
with Ab1-40. The sign convention is ‘influx positive’. While K
+ flux
remained similar in control and cells treated with Ab for one and
three days, an increase in duration of the treatment to six days or
longer led to a four-fold increase in K
+ efflux from the neural cells
(**P < 0.02). No difference in the levels of Ca
2+ fluxes between
control and Ab treated cells was observed. Error bars are SEM (n =
4-7).
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+ and Ca
2+
were monitored continuously throughout the experi-
ment starting before the glutamate challenge and up to
30 min afterwards with data acquired every 6 sec. Typi-
cal examples of kinetics of net K
+ and Ca
2+ fluxes in
response to challenge with glutamate are shown in Fig-
ures 4A-B and 5A-B, respectively.
Acute treatment of cortical neurons with 10 μM gluta-
mate led to a dramatic K
+ efflux from neurons that
returned to pre-stress conditions within 20 min after
the challenge (Figures 4A, B). Notably, the magnitude of
K
+ efflux was higher in cells treated with Ab for six
days or longer (peak values in the graphs). We therefore
compared the magnitudes of the peak K
+ efflux from
neurons treated with Ab with age-similar controls and
found that K
+ efflux was substantially (1.6-fold) higher
even after one day of treatment with soluble Ab1-40 (Fig-
u r e6 A ) .T h i sd i f f e r e n c ew a sm o r ep r o n o u n c e dw i t h
increase of duration of the treatment with Ab leading to
more than 3.5-fold increase in the peak K
+ efflux after
six and eight days of treatment with soluble monomeric
Ab1-40 (1 μM), (Figure 6A).
We also assessed capacity of the cortical neurons to
return K
+ flux to pre-stress levels after glutamate chal-
lenge. For this we compared steady-state values of K
+
fluxes 20 min after glutamate challenge in Ab treated
and age-similar un-treated control neurons (Figure 6B).
While the level of K
+ flux had returned to basal levels
in non Ab treated cells, this was not the case when neu-
rons had received continual treatment with Ab, suggest-
ing that Ab1-40 treated neurons have reduced capacity to
maintain K
+ homeostasis in response to glutamate sti-
mulation. We also calculated total K
+ efflux over 20 min
after acute glutamate application shown as shaded area
in Figure 4B. Total amount of K
+ efflluxed from the
cells over 20 min post glutamate application was sub-
stantially higher after treatment with low concentration
of Ab for six days or longer. For example, it was 2.8-
fold higher in cells pre-treated with Ab for six days than
in age-similar controls (22228.1 ± 2800.13 vs 8033.46 ±
3799.76 nmol m
-2, respectively, P < 0.05) further sug-
gesting dysregulation of K
+ homeostasis in Ab treated
cells.
Chronic Ab treatment leads to increased Ca
2+uptake by
cortical neurons in response to glutamate challenge
We similarly used MIFE to examine Ca
2+ fluxes follow-
ing glutamate challenge to control and Ab treated corti-
cal neurons. Neurons which had been exposed to
glutamate challenge (10 μM) rapidly took up Ca
2+ fol-
lowed by a return to pre-stress levels (Figure 5A, B). In
neurons which had been exposed to Ab for one and
three days, glutamate induced an influx of Ca
2+ that was
not statistically different from age-similar control cells
(Figure 7A). However, cortical neurons that received
soluble Ab1-40 for six consecutive days or longer had a
significant impairment in their ability to maintain Ca
2+
homeostasis, resulting in significantly greater Ca
2+
uptake following excitotoxic stimulation with glutamate
(Figure 7A). The magnitude of the peak Ca
2+ influx was
substantially higher in Ab-treated cells than in the age-
similar control cells (Figure 7A). At the same time
Figure 3 Neuronal viability in response to glutamate treatment following seven days of daily Ab1-40 treatment.T r e a t m e n tw i t h
glutamate significantly reduced neuronal viability of cultured cortical neurons by approximately 20% compared to untreated cells (A). When
neurons were pre-treated with 1 μMA b1-40 for seven days, challenge with 200 μM glutamate for 24 hours resulted in a comparable degree of
neuronal death compared to unchallenged, Ab1-40 -treated cells (B). *P < 0.05 between treatments. All data are means ± SEM, n = 6.
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2+ fluxes measured 20 min after
the glutamate challenge were not statistically different
from the relevant values of age-similar control cells even
after six and eight days of Ab treatment, despite an
apparent trend towards an increase in Ca
2+ flux values
(Figure 7B). However, a calculation of total Ca
2+ uptake
over 20 min of treatment with glutamate, showed that
the amount of Ca
2+ taken up by Ab treated cells was
2.5-fold higher than in age-similar un-treated control
cells after six days of treatment with Ab (7964.47 ±
672.84 vs 3156.41 ± 1615.93 nmol m
-2, respectively, P <
0.05) further confirming Ca
2+ dysregulation in cortical
neurons after prolonged exposure to a soluble Ab.
Discussion
Chronic exposure to Ab1-40 is neurotoxic to cultured
cortical neurons
The accumulation of Ab protein in the brain is consid-
ered to be a key factor that causes AD. Most cultured
cell models have examined the acute toxicity of Ab,
typically following 24 h treatment [6] which may not
reflect the situation in vivo. In this study we examined
the effect of daily exposure to moderate levels of solu-
ble, monomeric Ab1-40 (1 μM) for up to seven days and
demonstrated, for the first time, that chronic exposure
of primary cortical neurons to levels of Ab which have
no evident effect on viability over the short term, are
indeed neurotoxic. A decrease in cell survival was only
observed after seven days of exposure to 1 μMA b,w i t h
a 20% decrease in cell viability. This finding indicates
that Ab1-40 accumulation over time can induce
Figure 4 Kinetics of K
+ flux in response to acute application of
10 μM glutamate.K
+ flux was measured from age-similar control
cells (A) and primary cortical neurons treated daily with 1 μMA b1-40
for six days (B). Flux values were recorded for 5 min before
glutamate application (-5 to 0 min) and 25 min afterwards with
data acquired at a rate of 10 samples/sec and averaged over every
6 sec. Glutamate (10 μM) was applied at zero time as indicated by
an arrow and led to a transient K
+ efflux from neurons that
returned to pre-stress conditions within 15 min afterwards. Notably,
the magnitude of K
+ efflux was higher in Ab treated cells as shown
by comparison of the peak values. Negative values of K
+ flux
indicate “efflux”. Shaded area in panel B indicates total K
+ efflux
over 20 min after glutamate treatment. One (out of 7) typical
example is shown.
Figure 5 Kinetics of Ca
2+ fluxes in response to acute
application of 10 μM glutamate.C a
2+ fluxes were measured from
age-similar control cells (A) and primary cortical neurons treated
daily with 1 μMA b1-40 for six days (B). Flux values were recorded
for 5 min before glutamate application (-5 to 0 min) and 25 min
afterwards with data acquired at a rate of 10 samples/sec and
averaged over every 6 sec. Glutamate (10 μM) was applied at zero
time as indicated by an arrow and led to Ca
2+ influx into cultured
cortical neurons (positive flux values). One (out of 7) typical example
is shown.
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bute to the slowly progressing pathogenesis of AD.
Chronic exposure to Ab1-40 impairs K
+ homeostasis in
cortical neurons
Using MIFE, we observed an increase in K
+ efflux con-
current with the decline in neuronal viability. While
acute treatment with 1 μMA b did not affect net fluxes
of K
+ nor Ca
2+ (Additional file 1: Figure S1) confirming
earlier findings regarding intracellular Ca
2+ changes
[19], here we demonstrate that prolonged treatments
with low concentrations of Ab1-40 led to dysregulations
of K
+ but not Ca
2+ homeostasis. This is in agreement
with an earlier demonstration that exposure of neurons
to Ab peptide can enhance voltage gated K
+ currents
[20-22]. For example, preincubation of cells with recom-
binant human or rat Ab1-40 was shown to significantly
increase K
+ channel current density and levels for Kv4.2
[15]. Studies on brain slices at different stages of AD
demonstrated that voltage gated K
+ currents were
already overexpressed in early stages of AD, and in
advanced AD stages Kv3.4 was present at high levels in
neurodegenerative structures [23]. Other studies also
Figure 6 Effect of glutamate application on K
+ fluxes.
Glutamate (10 μM) was applied to cortical neurons following daily
treatment with 1 μMA b1-40, and to age-matched un-treated control
cells. Peak values of K
+ fluxes (A) and steady-state K
+ fluxes
recorded 20 min after glutamate application (B) are shown for one,
three, six, and eight days of treatment with Ab. Peak K
+ efflux was
substantially (1.6-fold) higher after one day of treatment with
soluble Ab1-40 than in age-similar control cells and further increased
to 5.7-fold difference after six days of treatment. The capacity of
cortical neurons to retain K
+ flux at pre-stress levels after glutamate
challenge was assessed by comparing steady-state values of K
+
fluxes 20 min post-treatment. K
+ efflux in Ab treated cells was
significantly higher than in age-similar controls after treatment with
Ab suggesting that Ab accumulation by neurons reduces their
ability to maintain K
+ homeostasis. * - P < 0.05, ** - P < 0.02, t-test.
Error bars represent SEM (n = 4-7).
Figure 7 Effect of glutamate application on Ca
2+ fluxes.
Glutamate (10 μM) was applied to cortical neurons following daily
treatment with 1 μMA b1-40, and to age-matched un-treated control
cells. Peak values of Ca
2+ fluxes (A) and steady-state Ca
2+ fluxes
recorded 20 min after glutamate application (B) are shown for one,
three, six, and eight days of treatment with Ab. Glutamate
application to the bath induced a mild Ca
2+ influx in primary
cortical neurons with peak values being not statistically different
from the relevant Ca
2+ peak values recorded from age-similar
control cells one and three days after the treatment. However,
treatment with soluble Ab for six days and longer increased Ca
2+
uptake by more than two-fold as compared with non-treated age-
similar control cells (* - P < 0.05, t-test). While steady-state values of
Ca
2+ fluxes measured 20 min after the glutamate challenge were
not statistically different from the relevant values of age-similar
control cells even after six days of Ab treatment (Figure 7B; P < 2.0
at n = 7), the calculated total amount of Ca
2+ taken up by Ab
treated cells over 20 minutes of treatment with glutamate was 2.5-
fold higher than in age-similar un-treated control cells (P < 0.05).
Error bars represent SEM (n = 4-7).
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+/K
+-ATPase. For instance, it was shown that exposure of
cultured neurons to Ab1-40 caused selective reduction in
Na
+/K
+-ATPase activity which preceded loss of Ca
2+
homeostasis and cell degeneration [24]. This was further
confirmed in studies using APP and PS1 deficient mice
[25]. Together, enhancements of voltage gated K
+ chan-
nels and decrease in Na
+/K
+-ATPase activity would
increase overall K
+ efflux, similar to Ab effects observed
in our experiments. The decrease in intracellular K
+
concentration is also consistent with a decrease in cell
viability since this is required for apoptosome formation
and activation of caspases and endonucleases during
apoptosis [26,27].
Exposure to glutamate further decreased impaired
neuronal ability to maintain K
+ homeostasis in cells
chronically treated with Ab1-40
A growing body of evidence suggests that perturbations
in systems using the excitatory amino acid L-glutamate
may underlie chronic neurodegenerative disorders such
a sA D .T h e r e f o r e ,w ei n v e s t i g a t e dw h e t h e rp r o l o n g e d
exposure to 1 μMA b1-40 increased neuronal susceptibil-
ity to subsequent acute excitotoxicity induced by gluta-
mate. Surprisingly, no further decrease in neuronal
viability was observed when cortical neurons treated
with Ab for seven days were exposed to glutamate (Fig-
ure 3A, B). Likewise, an earlier study has shown that
low concentrations of Ab peptide induced early and
prolonged activation of proapoptoic markers in neurons
without resulting in subsequent cell death in culture
[28] most likely due to additional protective mechanisms
in place at glutamate concentrations used. However,
despite the absence of an overt change in neuronal via-
bility following the combined treatments, we demon-
s t r a t e dt h a te x p o s u r et oA b perturbed the ability of
neurons to maintain K
+ homeostasis following glutamate
treatment. Treatments with 1 μMA b for one day were
sufficient to lead to glutamate induced K
+ dyshomeosta-
sis in cortical neurons (Figures 6A, B). Indeed, peak K
+
efflux after acute exposure to 10 μM glutamate was sub-
stantially higher in Ab treated cells than in age-similar
controls. This difference increased with time of Ab
exposure from 1.6 to 4.8-fold for one and six days of
the treatment, respectively. Neurons were also unable to
return K
+ to pre-stress level as shown for steady-state
K
+ fluxes measured 20 minutes after the treatment with
glutamate (Figure 6B). Another consequence of chronic
pretreatment with Ab was a higher level of K
+ efflux
even before challenge with glutamate (shown in Figure 2
for initial K
+ values). Overall, this led to a 2.9-fold
higher amount of K
+ efflux from cells treated with
Ab1-40 for six days or longer after glutamate application
than from age-similar control cells over 20 min of
glutamate exposure. Taken together, our data suggest
that chronic Ab treatment impairs the ability of cortical
neurons to maintain K
+ homeostasis.
Prolonged Ab exposure increased Ca
2+uptake by cortical
neurons in response to acute glutamate treatment
Ca
2+ homeostasis undergoes subtle dysregulation during
physiological ageing making neurons more vulnerable to
additional stress which, in turn, can lead to neuronal
degeneration. Recent evidence strongly supports the the-
ory that dysregulation of intracellular Ca
2+ homeostasis
underlies the development of AD [12-14]. Therefore, we
investigated whether prolonged exposure to continuous
Ab1-40 treatment followed by glutamate challenge would
affect Ca
2+ homeostasis in cortical neurons. Acute treat-
ment with 10 μM glutamate after chronic pre-treatment
with 1 μMA b1-40 in our experiments led to net Ca
2+
uptake from external environment (Figure 5B). An
increase in glutamate concentration leads to activation
of ionotropic and metabotropic receptors [29,30] and
Ca
2+ influx through both glutamate-dependent pathways
and voltage-dependent Ca
2+ channels [31-33]. While the
observed Ca
2+ uptake in response to acute glutamate
treatment was expected, in the current study we showed
that the magnitude of Ca
2+ uptake was substantially
increased in cells treated with 1 μMA b1-40 for six con-
secutive days or longer compared to un-treated control
cells (Figure 7A). Calculated total Ca
2+ taken up by Ab
treated cells over 20 min post glutamate application was
2.5-fold higher than in age-similar untreated control
cells (P < 0.05) suggesting dysregulation of Ca
2+ home-
ostasis in cortical neurons after prolonged exposure to
soluble Ab. Overall, our data showed that prolonged Ab
accumulation renders cortical neurons more vulnerable
to excitotoxicity leading to their inability to maintain
Ca
2+ homeostasis when glutamate concentration
increases.
Conclusions
In this study we developed an in vitro model to test the
effects of prolonged Ab treatment. We demonstrated for
the first time that continuous exposure to low levels of
Ab1-40 induced neurodegeneration of cultured cortical
neurons, with decreased viability evident after seven
days of treatment. This decrease in viability correlated
with increased neuronal K
+ efflux. We also demon-
s t r a t e dt h a tl o n gt e r me x p o s u r et oA b1-40 leads to
imbalance in K
+ and Ca
2+ homeostasis and contributes
to glutamate-induced vulnerability and cell death at
later time point. This suggests that chronic accumula-
tion of low levels of Ab1-40 may contribute to the slowly
progressing pathogenesis of AD. The results also suggest
that the inability to maintain ion homeostasis is an early
indicator of cell vulnerability that precedes cell death
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ity to the excytotoxic treatment.
Methods
Rodent cortical neuron cultures
Cortical tissue was removed from embryonic day 18
Hooded Wistar rat embryos and incubated in sterile 10
mM HEPES buffer (37°C; Sigma). The cortical tissue
was trypsinised (0.25%; Sigma) and washed with fresh
HEPES buffer. The cell pellet was gently triturated and
filtered through 60 μm gauze. Cells were then plated
o n t og l a s sc o v e r s l i p s( 2 5 4m m
2) pre-coated overnight
with poly-L-lysine (Sigma) at the density of 1 × 10
5
cells/well and culture medium added to the wells. The
culture medium consisted of Neurobasal™ medium
(Gibco), supplemented with 10% FCS (Gibco), 2% (f/c)
B-27 supplement (Gibco), 5 mM (f/c) L-glutamine
(Sigma), and 10 mg/ml gentamycin (Sigma). Cultures
were maintained at 37°C in humidified air containing
5% CO2. The culture medium was replaced with serum-
free culture medium after 24 hours, followed by a full
media change three times a week.
Ab treatment and toxicity assay
1 μMA b1-40 was applied to 6 DIV cortical neuron cul-
tures daily for 7 days. Fresh media was applied a week.
A biological reducing agent, 300 μM ascorbate (the phy-
siological concentration within the brain), was freshly
applied with each media change for both control and
the treatment. At days 2, 3, 4, 6, and 7 the neuronal via-
bility was measured using an Alamar Blue assay, which
measures cellular metabolic activity [34]. The degree of
cellular metabolic reduction of Alamar Blue was deter-
mined by fluorescence (excitation 535 nm, emission 595
nm), and expressed as the percentage of the signal
obtained from the vehicle-treated culture. Day zero was
the first day of treatment
Neural survival following chronic Ab treatment
To examine whether Ab treatment increased neuron
susceptibility to excitotoxicity, 6 DIV cultures treated
daily with 1 μMo fs o l u b l eA b1-40 for seven days were
exposed to 200 μM glutamate. Glutamate was prepared
as we have reported previously [35]. Briefly, D-glutamic
acid was dissolved in appropriate medium (Neurobasal
medium for viability assay and aCSF for MIFE experi-
ments). Neuronal viability was measured using the Ala-
mar Blue assay after 24 hours of glutamate treatment.
Ion-selective flux measurements
The technique of Microelectrode ion flux estimation
(MIFE) has been reviewed recently [18] and the complete
experimental procedure including ion-selective micro-
electrode fabrication and cell preparation and
immobilisation are given elsewhere [17,18]. Cortical neu-
rons for the MIFE measurements were grown for 6 days
at 1 × 10
5 cells/well on coverslips coated with poly-L-
lysine as described above. By 6 DIV a dense monolayer of
neurons had developed. Cells were washed in artificial
CSF (aCSF) by dipping a coverslip with cells into a beaker
with pre-warmed to 37°C aCMF. The coverslip then was
placed into a measuring chamber with 2 mL of aCMF at
37°C, and left for adaptation for a further 40 min at room
temperature (RT, 23°C) prior to an experiment. The
composition of the aCSF was: 150 mM NaCl, 0.5 mM
KCl, 0.5 mM CaCl2, 1.5 mM MgCl2,1 . 2 5m MN a H 2PO4,
2m MN a H C O 3, 25 mM glucose, pH 7.2. Measurements
were taken after one, three, six, and eight days post treat-
ment with Ab1-40. Control experiments used age similar
cells that were not pre-treated with Ab1-40. Additional
controls such as addition of vehicle (aCMF) and Ab1-40
were also used. For this co-focused K
+ and Ca
2+ micro-
electrodes were positioned ~5 μm above the cells and
moved by a computer-driven hydraulic micromanipulator
by 50 μma w a yf r o mt h ec e l l sa n db a c kt ot h ep r i m a r y
position with 0.05 Hz frequency. Data was acquired at a
rate of 10 samples/sec and averaged later over 6 second
intervals. The ion fluxes were recorded for 5 min prior to
the addition of 10 μM of glutamate, and recordings con-
tinued for a further 25 min. To achieve the required con-
centration of glutamate in the measuring chamber, an
equal volume of the bath solution with a double concen-
tration of glutamate was added resulting in the final con-
centrations of glutamate (10 μM). Net ion fluxes (nmol
m
-2s
-1) were calculated using planar geometry of diffu-
sion equations.
Statistical analyses of tissue culture experiments
For each experiment unless otherwise stated, a mini-
mum of four wells from at least three separate cultures
(derived from different animals), were used for quantifi-
cation. Statistical analysis was completed using SPSS
16.0 (SPSS). When data was unequally distributed, data
was transformed so that the residuals were approxi-
mately normally distributed. Statistical significance was
calculated using One-Way ANOVA with Tukey’sP o s t
Hoc Test and Student’s t-test.
Additional material
Additional file 1: Figure S1. Effects of acute application of Ab1-40 on
net K
+ and Ca
2+ fluxes. We tested whether acute application of Ab1-40
to 14 DIV cortical neurons affected magnitudes of K
+ and Ca
2+ fluxes.
Net fluxes of K
+ (A) and Ca
2+ (B) were recorded for 5 min (-5 to 0 min)
followed by acute application of 1 μMA b1-40 (0 to 10 min) and 40 μM
Ab1-40 (final concentration, 10 to 25 min) to the bath. Neither
concentration caused changes in net ion fluxes measured during the
time course tested suggesting that prolonged treatment with Ab1-40 is
required to trigger disturbances in ion homeostasis. Error bars are SEM (n
= 4).
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Page 8 of 10Additional file 2: Figure S2. Effects of experimental solution
application to the measuring chamber on ion fluxes. An additional
control was made to test a possible effect of solution disturbances in the
measuring chamber on ion fluxes. Neurons at 14 DIV were used. Net K
+
(A) and Ca
2+ (B) fluxes were recorded continuously for 5 min (-5 to 0
min) and after vehicle (aCSF) application to the bath (0 to 10 min) with
data acquired at a rate of 10 samples/sec and averaged over every 6 sec.
Vehicle was applied at zero time as indicated by an arrow. No changes
in K
+ and Ca
2+ fluxes were observed thus validating the approach used.
Error bars are SEM (n = 4).
Abbreviations
Ab: beta amyloid; AD: Alzheimer’s disease; APP: b-amyloid precursor peptide;
DIV: days in vitro; MIFE: microelectrode ion flux measuring technique.
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